Zepbound

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

High-dose semaglutide ramps up weight loss, says Novo

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

News

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

News

Patient using a positive airway pressure mask

Lilly grabs first-ever FDA nod for a sleep apnoea drug

Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.

News

Novo Nordisk sheds billions in value on obesity data

Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.

News

Ro co-founder and chief executive Zach Reitano

Lilly adds another sales channel for obesity drug Zepbound

Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel.

Lilly launches discounted high-strength Zepbound vials in US

High-dose semaglutide ramps up weight loss, says Novo

Lilly trims sales forecast on weaker obesity/diabetes growth

Lilly grabs first-ever FDA nod for a sleep apnoea drug

Novo Nordisk sheds billions in value on obesity data

Lilly adds another sales channel for obesity drug Zepbound

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Zepbound

Editor's Picks